Efficacy and Saffety of Oral Immunotherapy to Pistachio
NCT ID: NCT05698030
Last Updated: 2023-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2020-01-01
2023-01-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Threshold Dose Distribution for Pistachio Allergy
NCT06589232
Efficacy and Safety of Cashew Nut Oral Immunotherapy in Children
NCT05821621
Clinical and Biological Efficacy of Peanut Oral Immunotherapy
NCT02979600
Study of Tolerance to Oral Peanut
NCT01259804
Efficacy and Safety of Oral Cashew Nut Immunotherapy in Children (CAJESITO)
NCT05826405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Food allergy
Oral immunotherapy to pistachio
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have received oral immunotherapy to pistachio for at least 18 months at 31/12/2022
Exclusion Criteria
* Patients lost to follow-up for more than 2 years or last consultation dating from 2020 or earlier
1 Year
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amandine DIVARET-CHAUVEAU
MCU-PH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amandine DIVARET-CHAUVEAU
Role: PRINCIPAL_INVESTIGATOR
Centre hospitalo-universitaire de Nancy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalo-Universitaire de Nancy
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022PI182
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.